Vectibix® is indicated in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mCRC) with wild-type RAS.
Vectibx® is indicated as monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type RAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
License Holder: Amgen Europe B.V., Israel Branch
For full details please refer to the PI as approved by the IL MoH
Braftovi® – encorafenib is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an approved test, after prior therapy
For full details please refer to the PI as approved by the IL MoH
Lonsurf® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents
Lonsurf® in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy
Lonsurf® is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
For full details please refer to the PI as approved by the IL MoH.
